R&D
  • Core Technology Platforms

    Biostar is committed to the R&D of microbial metabolites innovative drugs, and has established advanced, unique and sustainable core technology platforms, including combinatorial biosynthesis, microbial fermentation production, microbial drugs formulation development platforms.


    Through combinatorial biosynthesis technology platform, we can conduct mechanism research of compound biosynthesis and drug molecular design, to identify the candidates with high druggablity. Then biosynthetic genes are modified by genetic engineering techniques, and homologous or heterologous host expression systems are constructed, to obtain modified strains with industrialization potential. Through microbial fermentation production technology platform, we can design the fermentation process, including the settings of culture medium and the study of CQAs. Through microbial drugs formulation development technology platform, we can solve the bottleneck of formulation for such molecules to improve the druggability and the compliance for clinical use.

  • Combinatorial Biosynthesis Technology

    Combinatorial biosynthesis belongs to the scope of synthetic biology.  In microbes, it is the process of producing innovative metabolites by continuously elucidating (discovery of metabolic mechanisms), designing (enzyme & pathway selection), editing (manipulation of biosynthetic gene cluster), building (bioproducer construction) and testing (product evaluation). Modern gene editing technology is used to change the biosynthetic functional genes or modules to construct innovative metabolic pathways and enzymes. These microorganisms can then be turned into "cell factories" to produce pharmaceuticals.

    Advantages: 

    (1) This key technology platform confers the creation of a series of unnaturally occurring natural compounds through alternative combinations of genes and modules of biosynthetic pathways,  increasing the effectiveness of  development of novel small molecule drugs  with high activity, low toxicity, good bioavailability, and high yield;

    (2) It is possible to obtain compounds with modified new structures that are difficult to be made by chemical synthesis;

    (3) The reaction conditions of biosynthesis are mild, the stereoselectivity is good during synthesis, the production cost is low, and the process is environmental friendly.



.